{
  "title": "Accelerated phase chronic myeloid leukemia: Diagnosis and treatment",
  "headings": [
    {
      "heading": "INTRODUCTION",
      "subheadings": []
    },
    {
      "heading": "PRETREATMENT EVALUATION",
      "subheadings": [
        "Clinical and laboratory",
        "History",
        "Physical examination",
        "Performance status",
        "Laboratory",
        "Clinical tests",
        "BCR-ABL1",
        "Bone marrow morphology",
        "Karyotype",
        "Mutation testing â€” BCR-ABL1",
        "Hematopoietic cell transplantation evaluation"
      ]
    },
    {
      "heading": "DIAGNOSIS OF AP CML",
      "subheadings": [
        "World Health Organization",
        "Other models",
        "European LeukemiaNet (ELN)",
        "MDACC (MD Anderson Cancer Center)",
        "Sokal"
      ]
    },
    {
      "heading": "MANAGEMENT",
      "subheadings": [
        "de novo versus transformed AP",
        "Treatment of de novo AP CML",
        "Selection of a TKI",
        "Outcomes",
        "Treatment of transformed AP CML",
        "Transplant-eligible",
        "Prior to transplantation",
        "Outcomes",
        "Not transplant-eligible"
      ]
    },
    {
      "heading": "TYROSINE KINASE INHIBITOR SELECTION",
      "subheadings": [
        "Mutation status",
        "TKI adverse effects",
        "Comorbid conditions",
        "Mutation-guided",
        "Comorbidity-guided",
        "Toxicity-guided"
      ]
    },
    {
      "heading": "2G tyrosine kinase inhibitors",
      "subheadings": [
        "Dasatinib",
        "Nilotinib",
        "Bosutinib",
        "Ponatinib"
      ]
    },
    {
      "heading": "OTHER TREATMENTS",
      "subheadings": [
        "Asciminib",
        "Omacetaxine mepesuccinate",
        "Interferon",
        "Others"
      ]
    },
    {
      "heading": "RESPONSE MONITORING",
      "subheadings": [
        "BCR-ABL1 monitoring",
        "Optimal responses"
      ]
    },
    {
      "heading": "PROGNOSTIC FACTORS",
      "subheadings": [
        "de novo versus transformed AP CML",
        "Major route additional chromosomal abnormalities",
        "Increased blasts",
        "Rate of response to treatment",
        "Molecular abnormalities"
      ]
    },
    {
      "heading": "SOCIETY GUIDELINE LINKS",
      "subheadings": []
    },
    {
      "heading": "INFORMATION FOR PATIENTS",
      "subheadings": [
        "Beyond the Basics topics"
      ]
    },
    {
      "heading": "SUMMARY AND RECOMMENDATIONS",
      "subheadings": [
        "Diagnosis of AP CML",
        "Distinguishing de novo AP CML from transformed AP CML",
        "Treatment of de novo AP CML",
        "Treatment for transformed AP CML",
        "Transplant-eligible",
        "Not transplant-eligible",
        "Selection of a TKI",
        "Response monitoring"
      ]
    },
    {
      "heading": "REFERENCES",
      "subheadings": []
    }
  ]
}